|
Market Closed -
Nasdaq
21:00:00 25/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 24.86 USD | +0.32% |
|
-6.33% | -14.39% |
| 08-24 | Oruka Therapeutics Names Chief Commercial Officer | MT |
| 08-20 | Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis | MT |
| Market Cap | 3.12B 2.68B 2.51B 2.29B 4.33B 298B 4.37B 29.59B 11.52B 150B 11.73B 11.48B 498B | P/E 2026 * |
64x | P/E 2027 * | 19.9x |
|---|---|---|---|---|---|
| Enterprise Value | 2.84B 2.43B 2.28B 2.08B 3.93B 270B 3.96B 26.86B 10.46B 136B 10.65B 10.42B 452B | EV / Sales 2026 * |
5.28x | EV / Sales 2027 * | 3.63x |
| Free-Float |
98.22% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Arcutis Biotherapeutics, Inc.
| 1 day | +0.32% | ||
| 1 week | -6.33% | ||
| Current month | -7.45% | ||
| 1 month | -9.10% | ||
| 3 months | +19.18% | ||
| 6 months | -7.96% | ||
| Current year | -14.39% |
| 1 week | 24.49 |  | 26.56 |
| 1 month | 24.49 | | 29.24 |
| Current year | 19.3 | | 30.75 |
| 1 year | 15.1 | | 31.77 |
| 3 years | 1.76 | | 31.77 |
| 5 years | 1.76 | | 31.77 |
| 10 years | 1.76 | | 40.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Todd Watanabe
CEO | Chief Executive Officer | 58 | 31/03/2017 |
| Corporate Officer/Principal | 71 | 02/12/2025 | |
Latha Vairavan
DFI | Director of Finance/CFO | - | 14/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Heron
CHM | Chairman | 55 | 30/11/2019 |
Todd Watanabe
BRD | Director/Board Member | 58 | 31/12/2015 |
Howard Welgus
BRD | Director/Board Member | 74 | 31/07/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/08/26 | Sell | Chief Technology Officer | -1,697 | 0.0014% | ||
| 17/08/26 | Fiscal year | Director | 12,922 | 0.0103% | ||
| 12/08/26 | Fiscal year | Chief Technology Officer | 20,100 | 0.0161% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.32% | -6.33% | +58.44% | +221.19% | 3.12B | |
| +0.61% | +2.88% | +45.63% | +0.39% | 83.24B | |
| -0.14% | +4.11% | -19.44% | -35.31% | 59.49B | |
| +14.36% | +152.27% | +526.55% | +41.90% | 63.41B | |
| +0.76% | +3.53% | +0.08% | +36.18% | 52.94B | |
| +1.86% | +3.13% | +11.49% | +174.36% | 49.86B | |
| +1.21% | +3.87% | +61.90% | -16.51% | 32.62B | |
| +1.36% | +5.06% | +53.04% | +103.13% | 26.29B | |
| +9.39% | +11.35% | +14.26% | +214.82% | 22.23B | |
| +3.89% | +1.08% | +61.82% | +112.10% | 17.22B | |
| Average | +3.35% | +17.82% | +81.38% | +85.23% | 41.04B | |
| Weighted average by Cap. | +3.49% | +27.11% | +101.32% | +50.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 537M 460M 431M 394M 743M 51.19B 751M 5.09B 1.98B 25.83B 2.02B 1.97B 85.53B | 686M 587M 550M 503M 949M 65.35B 958M 6.49B 2.53B 32.97B 2.57B 2.52B 109B |
| Net income | 51.79M 44.38M 41.58M 37.98M 71.69M 4.94B 72.39M 491M 191M 2.49B 194M 190M 8.25B | 168M 144M 135M 123M 232M 16.01B 235M 1.59B 619M 8.08B 630M 617M 26.74B |
| Net Debt | -288M -247M -232M -212M -399M -27.49B -403M -2.73B -1.06B -13.87B -1.08B -1.06B -45.94B | -638M -546M -512M -468M -883M -60.8B -891M -6.04B -2.35B -30.68B -2.39B -2.34B -102B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/08/26 | US$24.86 | +0.32% | 1,185,616 |
| 24/08/26 | US$24.78 | -1.20% | 1,128,432 |
| 21/08/26 | US$25.08 | -1.07% | 2,159,329 |
| 20/08/26 | US$25.35 | -4.20% | 3,289,276 |
| 19/08/26 | US$26.46 | -0.30% | 1,025,411 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ARQT Stock
Select your edition
All financial news and data tailored to specific country editions
